Basilea announced the receipt of a $30 million milestone payment this morning, as its leading antifungal, Cresemba, exceeded the predetermined sales threshold in Europe. The receipt of this significant sales milestone from European licensee Pfizer is a testament to the continued strong growth of Cresemba, despite its maturity, and thanks to its profile, which combines a broad spectrum with a favourable side-effect profile. Efforts at Basilea to prepare for the loss of exclusivity for Cresemba...

Basilea announced this morning that it has received a further $25 million in non-dilutive funding from BARDA to support the development...

Basilea announced this morning that it has acquired the global rights to the Phase 3-ready beta-lactam/beta-lactamase inhibitor,...